Navicixizumab (Anti-DLL4 & VEGF)
Product Specifications
CAS Number
1638338-43-8
Synonyms
OMP 305B83
Target
VEGFR
Applications
Protein Tyrosine Kinase
Additionnal Information
Navicixizumab is a bispecific monoclonal antibody targeting DLL4 and VEGF, with potential anti-angiogenic and antineoplastic activities. It has shown antitumor effects in multiple cancer types, with the most promising results in ovarian cancer. M.W 146.17 kDa
Storage Conditions
-80°C (avoid freeze-thaw cycles)
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC470633-100 1x 100 µL
Von Willebrand Factor (3E2D10), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400178-100 1x 100 µL
CD50 (ICAM-3) (186-2G9), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC681003-100 1x 100 µL
Mucin 5AC (MUC5AC) (58M1), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740266-100 1x 100 µL
Human IgG Immunoglobulin (IG266), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC882408-500 1x 500 µL
CD14 (Monocyte / Macrophage Marker) (LPSR/2408), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details